Cabergoline Tablets 0.25 mg, 0.5 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 0.25 mg, 0.5 mg

Reference Brands: Dostinex (US/EU)

Category: Women's Health

Cabergoline 0.25 mg and 0.5 mg tablets, a long-acting dopamine agonist used mainly for hyperprolactinaemia and lactation inhibition. For importers, distributors, hospital pharmacies and endocrine tender buyers.

Product Description:

Cabergoline is an ergot-derived dopamine agonist with a strong, long-lasting action at D2 receptors. In the pituitary it switches off prolactin release, and its long half-life allows dosing once or twice a week. This page lists tablets of 0.25 mg and 0.5 mg. A 0.25 mg tablet suits low starting doses in hyperprolactinaemia and the short regimen that suppresses established lactation.

Its main use is hyperprolactinaemia, idiopathic or due to a prolactin-secreting pituitary adenoma. European labels also cover inhibition or suppression of lactation after birth and, in some markets, Parkinson's disease as a second-line choice. Tablets are taken with food to ease nausea, and doses rise slowly against prolactin levels. Long-term use carries a risk of fibrosis, including heart valve disease, so labels call for an echocardiogram before treatment and at intervals afterwards. It is contraindicated in existing valvulopathy. Impulse control disorders are another warning. Antipsychotics and metoclopramide cancel its effect, and macrolides raise its levels.

Sourcing notes. Cabergoline is a prescription-only endocrine medicine, not a psychotropic drug. It is sensitive to moisture, and the reference product comes in a glass bottle with a desiccant, so ask how a generic is packed and which stability data support that pack. A CTD or ACTD dossier should include bioequivalence data and zone IVb stability for hot, humid climates. Storage is at room temperature. Ask for a CoA for each batch, the GMP certificate of the finished-product site and a CoPP, and check that the leaflet carries the fibrosis warnings.